COHANCE Cohance Lifesciences Q1 FY26 results (Apr–Jun 2025) and concall
Management summary
- Cohance Lifesciences delivered a resilient Q1 FY26, marking its first full quarter as a unified platform.
- While reported CDMO growth was muted by inventory de-stocking in two large commercial molecules, the underlying business showed robust momentum, particularly in niche modalities like ADCs and Oligonucleotides.
- Management is aggressively investing in global capacity and leadership to hit its ambitious 2030 growth targets.
Source: Inve concall analysis and management guidance record.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 676 | 840 | 549 |
| EBITDA | 237 | 229 | 112 |
| Net profit | 153 | 117 | 46 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Total Revenue Revenue · by 2030 · High confidence $1 billion (₹85 billion)
Margin
EBITDA Margin Margin · medium term · Medium confidence mid-30s
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Organic vs Inorganic Growth for FY26 Evasive
For us, the organic and inorganic are two sides of the same coin. It is about capital allocation... I would urge you guys to kind of think about it in the way we look at and not separating it as an organic or inorganic.
Management declined to provide a specific organic growth target for the current fiscal year, focusing instead on their M&A-led strategy.
Asked by Shyam Srinivasan
US Tariff Exposure and Supply Chain Direct
Most of our current agreements with the customers are on FOB basis. We do not have the liability to pay the tariffs, when the goods reach the shore of U.S.
Clarifies that the company has minimal financial exposure to potential US trade tariffs due to contract structures and product classification (intermediates vs APIs).
Asked by Avnish Burman
Unlock risks & concerns, Q2 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 3 risks, concerns & management red flags
- Watchlist triggers for Q2 FY26
- +3 more guidance targets & verbatim management quotes
- +1 more analyst Q&A exchange & evasion checks
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





